CLINICAL_TRIALS
trial_result
· 2016-11-02
Clinical Trial Update: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine). [Phase 3]
Summary
A Phase 3 clinical trial in breast cancer patients receiving capecitabine (Xeloda) to prevent hand-foot syndrome has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED